Your SlideShare is downloading. ×
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Deepak ppt
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Deepak ppt

230

Published on

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
230
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Presented by: Deepak Sahu (PGDPM) IIHMR Jaipur
  • 2. Aim of project: o To study & analyze the prescription habit of pediatrician for cough preparation. o To find out the mostly prescribed nasal decongestant by pediatrician. o To study & analyze the prescription pattern for respules. o Make the therapy map for children.
  • 3. Research Methodology  Data source primary data source.  Research approach descriptive survey research  Research instruments Questionnaires (multiple choice-closed ended and open ended questions)  Sampling plan a. Sampling unit: b. Sample size: c. Sampling procedures:  Contact method Personal Interview Pediatrician & Chemist 50 pediatrician & 30 chemist simple random sampling
  • 4. Areas covered during survey S.No Area covered No. Of Doctor No. of chemist 1 Sion 3 3 2 Villey parle 3 2 3 Gathkopar 4 3 4 Kalyan 5 4 5 Ullash nagar 3 1 6 Karla 5 4 7 Goregoan 4 3 8 Mulund 6 4 9 Bhandup 8 4 10 Bandra 4 11 Vashi 5 12 Marine line 1 13 Charni road 1 2
  • 5. Objective: To analyze how Paediatrician select the different combinations of cough preparation.
  • 6. Analysis : Prevalence of cough in children 2% 16% (0-5) (5-10) (10-15) 54% 20- more 28%
  • 7. Parameters for Selection of cough Preparations 10% 6% 2% 8% 8% Dose,molecule & Taste Clinical Study Platability, Safety & Side effect Cough History Cough Type Cause & Sine 66%
  • 8. Preferred molecule 4% 40% bronchodilator mucolytic suppressant & bronchodialator other 54% 2%
  • 9. Preferred flavor 22% 30% Mint Strawberry mixed Fruit orange 14% 34% Not specific
  • 10. Preferred parameter 18% Flavour 4% Pack size 2% recommendation 52% 14% Dosage titration Dosage form Price Other 8% 2%
  • 11. Finding & suggestions:  Prevalence of cough in children is more then other      disease. Basic parameters are cough type, cough history & cause. Most preferred molecule is Bronchodilator ,then suppressant. Majority of pediatrician preferred mixed fruits flavor & they are looking for palatability. Basic parameter while choosing any cough preparation are palatability, dose titration & pack size, then later on company & fso. We should organize some camp at dr. clinic for patient eduction.
  • 12. To find out the mostly prescribed nasal decongestant by pediatrician. No. Of patient 8% 8% 38% 10% (0-5) (5-10) (10-15) (15-20) 14% 20< Occasionally 22%
  • 13. Preferred molecule 4% 8% Normal Saline oxymethazone Xylomethazoline 88%
  • 14. Finding & suggestion:  40% of children with urti having nasal congestion.  Majority of Dr. having patient with nasal congetion.  Nasal congestion is the marketing driving molecule.  It takes 88% market share as per Rx wise.  But Xylometazoline & oxymetazoline are market follwing molecule.  This is another huge market for us to expanding the pediatric basket.
  • 15. To study uses of respiratory solution in children % of preference 8% Yes no 92%
  • 16. No. of patients 14% 30% (1-10) 14% (10-20) (20-30) 30-above seasonal 12% 30%
  • 17. Dr. preference to keep stock 42% Yes 58% No
  • 18. Preferred molecule 16% 8% Salbutamol/ levosalbutamol Ipratropium Budisonide Comb 14% 62%
  • 19. % Dr prefer inhalation 28% yes No 72%
  • 20. Market leader: S.No 1. Company Cipla Brand Schemed Percentage Astahlin 16+4 25 Duolin 18+2 10 Levolin 21+4 20
  • 21. Finding & suggestions:  92 % pediatrician prefer nebulization.  30 % of doctor prescribe respules on his routine practice.  58% of doctors are keeping stock of respules in his clinic or nursing home .  62% of Dr. prefer salbutamol & levosalbutamol as first choice for nebulization.  92% of market share is own by Cipla.
  • 22. Therapy map for children
  • 23. Demographic indicator:  Population: 1,029,991,145 (July 2001 EST.)  Age structure: -(0-14) years: 33.12% (male 175,630,537; female 165,540,672) -(15-64 )years: 62.2% (male 331,790,850; female 308,902,864)  Birth rate: 24.28 births/1,000 population (2001 EST.)
  • 24. Indication Total Rx-Jan MAT Rx-Jan MAT 09 10 Rx Grth 120,660 126,757 5 26,147 28,351 8 Diarrhea / Gastroenteritis 14,674 15,447 5 Lower respiratory infection 14,622 15,423 5 Fever 9,130 9,306 2 Viral infection 5,052 6,326 25 Bronchitis 4,450 4,918 11 Respiratory tract infection 2,971 2,650 -11 Acute Pharyngitis 2,810 2,645 -6 Chronic rhinitis / Pharyngitis 1,761 2,317 32 Asthma 2,340 2,261 -3 Abdominal and pelvic pain 2,029 2,175 7 Common cold 2,039 1,901 -7 Cough 1,857 1,876 1 Routine child health examination 1,790 1,822 2 Gastritis and duodenitis 1,640 1,792 9 Acute Respiratory tract infection
  • 25. Avg DrsMAT Jan 09 Specialty Rx-MAT Jan 09 Rx-MAT Jan 10 Rx Grth % Avg DrsMAT Jan 10 Rxer Grth Dispersion P/D-Mar Mat'10 All Doctors 1,493,927 1,576,544 6 228,645 239,579 5 100 548 G.P.(Non MBBS) 382,355 408,611 7 59,646 63,053 6 26.4 540 G.P.(MBBS) 219,344 220,291 0 30,076 29,806 -1 12.3 618 Consulting Physician 129,526 137,582 6 16,590 17,540 6 7.3 655 Dentist 128,010 136,903 7 24,867 26,774 8 11.2 427 Pediatrician 120,660 126,757 5 14,068 14,698 4 6.1 720 Gynecologist 116,450 123,236 6 21,194 21,882 3 9.1 470 Gen.Surgeon 63,176 67,019 6 9,837 10,105 3 4.2 552 Orthopaedic 57,897 62,445 8 9,280 9,845 6 4.1 527 Ophthalmologist 61,211 62,039 1 9,151 9,511 4 4.0 542 ENT Specialist 42,198 45,240 7 6,336 6,643 5 2.8 570 Cardiologist 35,505 38,267 8 5,287 5,611 6 2.3 569 Dermatologist 29,887 31,428 5 4,533 4,739 5 2.0 554 Chest TB Specialist 25,723 28,246 10 3,470 3,776 9 1.6 623 Neurologist Neuro Surgeon 19,049 21,023 10 3,329 3,666 10 1.5 478 Nephrologist Urologist 15,493 16,865 9 2,866 3,074 7 1.3 457 Diabetologist Endocrinologist 13,520 14,803 9 2,204 2,487 13 1.1 493 Psychiatrist 14,048 14,709 5 2,315 2,425 5 1.0 508 Gastroenterologist 13,007 14,167 9 2,241 2,466 10 1.0 475 Oncologist 6,867 6,912 1 1,356 1,481 9 0.6 384
  • 26. Speciality 9 95 9 1 10 10 5 10 0 1 1 11 8 2 2 2 7 3 1 G.P.(Non MBBS) G.P.(MBBS) 7 26 Dentist 4 8 Consulting Physician Paediatrician Gynaecologist 4 Gen.Surgeon 6 Orthopaedic 4 Ophthalmologist ENT Specialist 6 8 Cardiologist 14 Dermatologist 0 8 5 9 7 Chest TB Specialist Neurologist Neuro Surgeon 9 Nephrologist Urologist 6 Diabetologist Endocrinologist Psychiatrist
  • 27. Rx'000-Mar Mat'09 Rx'000PrescriptionsMar Mat'10 Rx Grth P/D-10 Peaadiatric 121,831 127,738 5 720 Anti-Infective 63,835 66,163 4 374 Respiratory 55,613 59,196 6 335 Pain / Analgesics 46,465 49,547 7 281 Others 43,078 45,692 6 261 Gastro Intestinal 31,773 33,842 7 192 Vitamins / Minerals / Nutrients 19,405 19,926 3 115 Derma 8,380 8,421 0 50 Anti-Parasitic 8,180 7,592 -7 47 Hormones 5,495 5,656 3 45 Gynaec. 4,297 4,559 6 31 Neuro / CNS 3,106 3,218 4 23 Anti-Malarials 3,083 2,808 -9 35 Ophthal / Otologicals 2,822 2,725 -3 19 Therapy
  • 28. Acid peptic disease / Acidity / Hyperacidity Conjunctivitis Constipation Chronic sinusitis Urticaria Skin infection Anorexia Typhoid and paratyphoid fevers Otitis media Dehydration Injury COPD Boil / Abscess Wheezing Malaria Acute tonsillitis Acute bronchitis UTI Helminthiases Anaemia Nausea and vomiting immunization Weakness / Malaise and fatigue Gastritis and duodenitis Routine child health examination Cough Common cold Abdominal and pelvic pain Asthma Chronic URTI Acute pharyngitis RTI Bronchitis Viral infection Fever LRTI Diarrhoea / Gastroenteritis Acute URTI 30,000 25,000 20,000 15,000 10,000 5,000 Series1 0 Series2
  • 29. N 2B NON-NARCOTICS,ANTIPYER. J 1D CEPHALOSPORINS R 5B COUGH PREPARATIONS M 1A ANTIRHEUMATIC NONSTR. J 1C AMPICILLIN AMOXYCILLIN R 5A COLD PREPARATIONS R 6A ANTIHISTAMINES,SYSTEMIC J 1F MACROLIDES AND SIMILAR R 3E BRONCHODILATORS LIQUIDS J 1L QUINOLONES A 7K OTH.INCL.LACTIC FERMENT R 1A NASAL DECONGESTANTS A 7L ORAL ELECTROLYTES A 4D ANTIEMET.,ANTINAUS LIQ. A11A MULTIVIT.WITH MINERALS H 2A SYS.CORTICOSTEROIDS PL. A11E VITAMIN B COMPLEX A 2B ANTIPEPTIC ULCERANTS P 1B ANTHELMINTICS EX.SCHIS. A 7G OFLOXACIN COMB. A 3C ANTISPASM.ANTICHOL. COMB. B 3A HAEMATINICS,IRON+COMB A 4C ANTIEMET.,ANTINAUS SOL. A 2A ANTACID,ANTIFLATULENTS A 9A DIGESTIVES INC.ENZYMES P 1D ANTIMALARIALS R 3C BRONCHODIL.INHALANT PREP. A12A CALCIUM PREP. D 6A TOP.ANTIBIOTICS PLAIN J 1K ALL OTHER ANTIBIOTICS R 3D BRONCHODILATORS SOLIDS A 7B NORFLOXACIN COMB. P 1A AMOEBICIDES A11B MULTVIT.WITHOUT MINERALS N 5B TRANQUILIZERS A12C OTHER MINERAL SUPPLEMENT A15A APPETITE STIMULANTS D 2A EMOLLIENTS,PROTECTIVES A 7M OTHER ANTIDIARRHOEALS J 7A PAEDIATRIC SINGLE VACCINE A 5B HEPATIC PROT.LIPOTROPIC S 1A ANTIINFECTIVES J 1E TRIMETHOPRIM COMB.& SIMI. S 2A OTOLOGICALS A 7A PLAIN INTEST.ANTIINFECT. A 4F ANTIEMET.,ANTINAUS COMB. 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0
  • 30. 25,000 Major Player 20,000 15,000 10,000 Series1 Series2 5,000 0
  • 31. Market driving molecules: 30,000 25,000 20,000 15,000 10,000 Series1 5,000 0 Series2
  • 32. Top 20molecule with growing trend
  • 33. S.n o Subgroup 1 Cepodoxime oral liq. 11147 33 2 Cefixime oral solid 52945 3 Cefpodoxime oral solid 4 MAT Mar 10 Value Grth Unit Grth (Value) (MAT Mar 10) (MAT Mar 10) Rx share% RX Grw% P/D Rx 33 16 7 41 23 29 13 11 35 27429 32 31 13 18 39 Cefixime oral liq. 9235 15 22 10 21 28 5 Cefadroxil oral liq. 2052 -1 -2 7 -21 24 6 Cefadroxil oral solid 13248 -8 0 6 -9 24 7 Amoxy & Clav.liq 15270 33 41 40 16 53 8 Amoxy & Clav.solid 36532 35 52 17 27 31 9 Amoxy solid 24106 10 -4 15 -5 36 10 Amoxy liq 6639 7 -1 13 -8 35 11 Azithromycin oral liq 31650 28 26 47 9 44 12 Azithromycin oral solid 5623 44 36 31 34 32 13 Erythromycin Liq 2360 14 16 5 10 17 14 Erythromycinoral solid 7406 7 9 5 -18 16
  • 34. S.n o Subgroup 15 MAT Mar 10 Value Grth Unit Grth (MAT (Value) (MAT Mar 10) Mar 10) Rx share% RX Grw% P/D Rx RANITIDINE ORAL SOLIDS 24528 12 -5 18 11 16 LANSOPRAZOLE 2016 14 2 15 36 19 PANTOPR.+ DOMPERID. 17763 33 26 10 91 22 PANTOPRAZOLE SOLIDS 18948 20 15 9 55 13 ORAL ELECTROLYTES 14597 27 17 85 10 48 Nasal Decongestant 13592 30 22 13 8 55 16 17 18 19 20
  • 35. Thank You

×